Blood: Tumor-targeted nanoparticles can improve the therapeutic effect of BCL2 and MCL1 double inhibition.

Center point: Double inhibition of MCL1 and BCL2 proteins can provide lasting relief to the DLBCL mouse model.
S63845 or Venetok encased in tumor-targeted nanoparticles can improve the therapeutic index of double inhibitory MCL1 and BCL2 proteins.
: Cancer and normal cells use a variety of anti-apoptosis BCL2 proteins to prevent cell death.
treatment of a variety of BCL2 family proteins in the region enhanced tumor killing, but was also associated with increased systemic toxicity.
recently, an article published in Blood, "Tumor Target Targetparticles Improve Index of BCL2 and MCL1 dual repression", found that the use of small molecules S63845 and Venetoclax to double-target inhibition of MCL1 and BCL2 proteins can lead to lasting in vivo remission in transplanted mice with human DLBCL tumors, but with blood toxicity and weight loss.
to mitigate these toxic side effects, Tannan et al. encapsulated S63845 or Venetok in nanoparticles that targeted P-selectives, which are rich in tumor endothoste cells.
in vivo show that nanoparticles are preferred to lymphoma cells compared to important organs.
analysis of the nanoparticle drug confirmed that the drug was rich in tumors and that the level of the drug in the plasma decreased.
addition, the use of nanoparticle-wrapped drugs reduced the dose of the drug applied by 3.5-6.5 times, ensuring continuous induced remission while keeping the toxicity of the drug to a minimum.
, the study supports the development and application of nanoparticles to transport BH3 similars in lymphoma, as well as the widespread use of toxic drugs in cancer treatment.
.